Halozyme, AbbVie deal

Halozyme said AbbVie discontinued the partners’ first program under a 2015 deal to develop AbbVie compounds using Halozyme’s Enhanze drug delivery platform. The platform uses recombinant human enzyme sperm adhesion molecule 1 (SPAM1; PH20) hyaluronidase to temporarily degrade hyaluronan and improve subcutaneous delivery of injectable biologics (see BioCentury, June 8, 2015). ...